Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

NCT04553068 ↗

Phase 3 Completed 1892 enrolled Evofem Inc.

RandomizedParallel-groupTriple-blindPrevention

Summary

This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection

Timeline

Start: 2020-10-15
Primary completion: 2022-07-28
Completion: 2022-07-28

Outcome

Missed primary endpoint

release “the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints” evofem.com ↗

Publications

Thomas MA, Morlock R, Dart C, Howard B. Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study. J Sex Med. 2022 Jun;19(6):975-982. doi: 10.1016/j.jsxm.2022.03.221. Epub 2022 Apr 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVO100	Other / unclassified	5 g	Other